Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sowing Seeds In Drug Discovery The Evotec Way: CEO Werner Lanthaler

Executive Summary

Evotec's hybrid drug discovery model continues to attract pharma partners and generate internal assets using what its CEO calls a "diversified seed sowing" business approach.

You may also be interested in...



Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships

Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.

Sanofi’s Larsen On Advances In Diabetes R&D And Payer Expectations

Dr Philip Larsen, Vice President, Research and Translational Medicine, R&D Diabetes Division, Sanofi tells Scrip in an interview which way potential gene therapy for diabetes may be headed and how the Sanofi-Evotec alliance is shaping. He also indicates that oral insulin, considered the holy grail of diabetes treatment, is a ‘really long journey’ with difficult prospects currently.

The Regenerative Market Brings The Future Closer

A clear sign the regenerative medicine and therapy market is making considerable progress comes from the amount of investor funding pouring into the space, and although a lot of the technology is still spoken about in the future tense, a variety of new companies are bringing the future much closer. An additional hallmark of the market is the role device companies are finding for themselves in an industry primarily lead by pharmaceutical businesses.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel